Should I buy or sell Coherus BioSciences stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CHRS shares. View CHRS analyst ratings or view top-rated stocks .

What is Coherus BioSciences' stock price target for 2024?

6 equities research analysts have issued 12 month price targets for Coherus BioSciences' stock. Their CHRS share price targets range from $6.00 to $12.00. On average, they anticipate the company's stock price to reach $9.29 in the next year. This suggests a possible upside of 364.3% from the stock's current price. View analysts price targets for CHRS or view top-rated stocks among Wall Street analysts .

How have CHRS shares performed in 2024?

Coherus BioSciences' stock was trading at $3.33 at the start of the year. Since then, CHRS stock has decreased by 39.9% and is now trading at $2.00. View the best growth stocks for 2024 here .

Are investors shorting Coherus BioSciences?

Coherus BioSciences saw a decline in short interest in March. As of March 31st, there was short interest totaling 23,450,000 shares, a decline of 9.5% from the March 15th total of 25,910,000 shares. Based on an average trading volume of 3,790,000 shares, the short-interest ratio is currently 6.2 days. View Coherus BioSciences' Short Interest .

When is Coherus BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our CHRS earnings forecast .

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) issued its quarterly earnings results on Wednesday, March, 13th. The biotechnology company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by $0.39. The biotechnology company earned $91.52 million during the quarter, compared to the consensus estimate of $105.30 million.

What ETFs hold Coherus BioSciences' stock?

ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) and First Trust Innovation Leaders ETF (ILDR) . Invesco Nasdaq Future Gen 200 ETF (QQQS) .

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com . Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO) , Chembio Diagnostics (CEMI) , Exelixis (EXEL) , Heron Therapeutics (HRTX) , TG Therapeutics (TGTX) , Intelsat (I) , Idera Pharmaceuticals (IDRA) , Immunomedics (IMMU) , Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX) .

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.17%) and RFG Advisory LLC (0.05%). Insiders that own company stock include Dennis M Lanfear , James Healy and Mcdavid Stilwell . View institutional ownership trends .

How do I buy shares of Coherus BioSciences?

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Coherus BioSciences have any subsidiaries?

The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc.. Read More

Positive News SentimentPositive News

NASDAQ:CHRS

Coherus BioSciences (CHRS) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free CHRS Stock Alerts

$2.07

+0.07 (+3.50%)

(As of 05:21 PM ET)

Compare

Today's Range: $1.95
▼
$2.09
50-Day Range: $2.00
▼
$2.85
52-Week Range: $1.43
▼
$8.33

Volume: 2.88 million shs
Average Volume: 3.86 million shs
Market Capitalization: $234.94 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.29

Get Coherus BioSciences alerts:

Coherus BioSciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 364.3% Upside
$9.29 Price Target
Short Interest: Healthy
20.66% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.08
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.56) to $0.11 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.24 out of 5 stars

Medical Sector

172nd out of 918 stocks

Biological Products, Except Diagnostic Industry

17th out of 151 stocks

3.4

Analyst's Opinion

Consensus Rating
Coherus BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Coherus BioSciences has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
20.66% of the outstanding shares of Coherus BioSciences have been sold short.
Short Interest Ratio / Days to Cover
Coherus BioSciences has a short interest ratio ("days to cover") of 6.2.
Change versus previous month
Short interest in Coherus BioSciences has recently decreased by 9.49%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Coherus BioSciences does not currently pay a dividend.
Dividend Growth
Coherus BioSciences does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Coherus BioSciences has received a 69.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Pegfilgrastim", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Coherus BioSciences is -1.08.

2.7

News and Social Media Coverage

News Sentiment
Coherus BioSciences has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Coherus BioSciences this week, compared to 3 articles on an average week.
Search Interest
Only 14 people have searched for CHRS on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Coherus BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Coherus BioSciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.99% of the stock of Coherus BioSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
72.82% of the stock of Coherus BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Coherus BioSciences are expected to grow in the coming year, from ($0.56) to $0.11 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Coherus BioSciences is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Coherus BioSciences is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Coherus BioSciences Stock (NASDAQ:CHRS)

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

CHRS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CHRS Stock News Headlines

April 11, 2024 | finance.yahoo.com

Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years

April 11, 2024 | americanbankingnews.com

Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Average Rating of "Moderate Buy" from Analysts

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 8, 2024 | finanznachrichten.de

Coherus BioSciences, Inc.: Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

April 8, 2024 | globenewswire.com

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

March 21, 2024 | seekingalpha.com

Coherus Biosciences: Dumping One Drug But Showing Promise With Another

March 16, 2024 | finance.yahoo.com

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript

March 15, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Solid Biosciences (SLDB)

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 15, 2024 | markets.businessinsider.com

Coherus Biosciences: Strong Q4 Performance and Strategic Moves Merit Outperform Rating

March 15, 2024 | finance.yahoo.com

Coherus BioSciences Full Year 2023 Earnings: EPS Misses Expectations

March 14, 2024 | fool.com

Why Coherus Biosciences Stock Tumbled on Thursday

March 14, 2024 | seekingalpha.com

Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript

March 14, 2024 | finance.yahoo.com

Q4 2023 Coherus BioSciences Inc Earnings Call

March 13, 2024 | benzinga.com

Recap: Coherus BioSciences Q4 Earnings

March 13, 2024 | markets.businessinsider.com

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

March 13, 2024 | msn.com

Coherus BioSciences Non-GAAP EPS of -$0.62 misses by $0.52, revenue of $91.5M beats by $1.07M

March 13, 2024 | finance.yahoo.com

Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ...

March 13, 2024 | globenewswire.com

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

March 12, 2024 | msn.com

Coherus BioSciences Q4 2023 Earnings Preview

March 6, 2024 | finance.yahoo.com

In the wake of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) latest US$49m market cap drop, institutional owners may be forced to take severe actions

March 5, 2024 | globenewswire.com

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

March 4, 2024 | finanznachrichten.de

Coherus BioSciences, Inc.: Coherus Completes Divestiture of Ophthalmology Franchise

March 4, 2024 | globenewswire.com

Coherus Completes Divestiture of Ophthalmology Franchise

February 23, 2024 | globenewswire.com

Coherus BioSciences Announces New Employment Inducement Grants

February 21, 2024 | benzinga.com

Coherus BioSciences Stock (NASDAQ:CHRS), Short Interest Report

February 21, 2024 | finance.yahoo.com

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

See More Headlines

Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:CHRS
CUSIP: N/A
CIK: 1512762
Web: www.coherus.com
Phone: (650) 649-3530
Fax: N/A
Employees: 306
Year Founded: 2010

Price Target and Rating

Average Stock Price Target: $9.29
High Stock Price Target: $12.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +364.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-237,890,000.00
Net Margins: -92.48%
Pretax Margin: -92.62%
Return on Equity: N/A
Return on Assets: -44.16%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.43
Quick Ratio: 1.24

Sales & Book Value

Annual Sales: $257.24 million
Price / Sales: 0.88
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.74) per share
Price / Book: -1.15

Miscellaneous

Outstanding Shares: 113,498,000
Free Float: 101,025,000
Market Cap: $227.00 million
Optionable: Optionable
Beta: 0.54

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Dennis M. Lanfear (Age 69)
Chairman, President & CEO
Comp: $1.79M
Mr. Bryan J. McMichael (Age 46)
Interim CFO, Principal Financial and Accounting Officer, SVP-Accounting & Corporate Controller
Mr. Richard L. Hameister
Chief Technical Officer
Ms. Jami Taylor
Vice President of Investor Relations
Cheston Turbyfill
Vice President of Communications
Mr. Scott Saywell
Executive Vice President of Corporate Development
Ms. Rebecca Sunshine (Age 61)
Chief Human Resources Officer
Mr. Michael Chen
Senior Vice President of Commercial Analytics & Trade
Mr. Paul Reider (Age 55)
Chief Commercial Officer
Dr. Theresa M. Lavallee Ph.D. (Age 58)
Chief Development Officer & Chairman of Scientific Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CHRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Coherus BioSciences stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CHRS shares.
View CHRS analyst ratings or view top-rated stocks.
What is Coherus BioSciences' stock price target for 2024?: 6 equities research analysts have issued 12 month price targets for Coherus BioSciences' stock. Their CHRS share price targets range from $6.00 to $12.00. On average, they anticipate the company's stock price to reach $9.29 in the next year. This suggests a possible upside of 364.3% from the stock's current price.
View analysts price targets for CHRS or view top-rated stocks among Wall Street analysts.
How have CHRS shares performed in 2024?: Coherus BioSciences' stock was trading at $3.33 at the start of the year. Since then, CHRS stock has decreased by 39.9% and is now trading at $2.00.
View the best growth stocks for 2024 here.
Are investors shorting Coherus BioSciences?: Coherus BioSciences saw a decline in short interest in March. As of March 31st, there was short interest totaling 23,450,000 shares, a decline of 9.5% from the March 15th total of 25,910,000 shares. Based on an average trading volume of 3,790,000 shares, the short-interest ratio is currently 6.2 days.
View Coherus BioSciences' Short Interest.
When is Coherus BioSciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our CHRS earnings forecast.
How were Coherus BioSciences' earnings last quarter?: Coherus BioSciences, Inc. (NASDAQ:CHRS) issued its quarterly earnings results on Wednesday, March, 13th. The biotechnology company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by $0.39. The biotechnology company earned $91.52 million during the quarter, compared to the consensus estimate of $105.30 million.

What ETFs hold Coherus BioSciences' stock?: ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) and First Trust Innovation Leaders ETF (ILDR).Invesco Nasdaq Future Gen 200 ETF (QQQS).
What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?: 21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Coherus BioSciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).
Who are Coherus BioSciences' major shareholders?: Coherus BioSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.17%) and RFG Advisory LLC (0.05%). Insiders that own company stock include Dennis M Lanfear, James Healy and Mcdavid Stilwell.
View institutional ownership trends.
How do I buy shares of Coherus BioSciences?: Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Coherus BioSciences have any subsidiaries?: The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..
Read More

This page (NASDAQ:CHRS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial